Chris Chapman
Corporate Officer/Principal en Dermavant Sciences Ltd. .
Perfil
Chris Chapman is currently the Chief Commercial Officer at Dermavant Sciences Ltd.
Prior to this, he attended Towson University for his undergraduate degree.
Cargos activos de Chris Chapman
| Empresas | Cargo | Inicio |
|---|---|---|
Dermavant Sciences Ltd.
 Dermavant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom. | Corporate Officer/Principal | 22/01/2020 |
Formación de Chris Chapman.
| Towson University | Undergraduate Degree |
Experiencias
Funciones ocupadas
Activas
Inactivas
Empresas cotizadas
Empresas privadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas privadas | 1 |
|---|---|
Dermavant Sciences Ltd.
Dermavant Sciences Ltd. Pharmaceuticals: MajorHealth Technology Dermavant Sciences Ltd. is a clinical-stage biopharmaceutical company which focuses on developing and commercializing therapeutics in medical dermatology. The company is developing a pipeline of therapies in medical dermatology and is currently advancing development programs for five product candidates which targets specific unmet needs in two of the immuno-dermatology markets, psoriasis and atopic dermatitis, as well as other large markets, including vitiligo, primary focal hyperhidrosis and acne. The company was founded on September 28, 2015 and is headquartered in London, the United Kingdom. | Health Technology |
- Bolsa de valores
- Insiders
- Chris Chapman